Literature DB >> 2374139

3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole.

J E Macor1, C A Burkhart, J H Heym, J L Ives, L A Lebel, M E Newman, J A Nielsen, K Ryan, D W Schulz, L K Torgersen.   

Abstract

The synthesis and in vitro and in vivo characteristics of 3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one (1, CP-93,129) are described. This rotationally restricted phenolic analogue of RU-24,969 is a potent (15 nM) and selective (200x vs the 5-HT1A receptor, 150x vs the 5HT1D receptor) functional agonist for the 5-HT1B receptor. Direct infusion of 1 into the paraventricular nucleus of the hypothalamus of rats significantly inhibits food intake, implicating the role of 5-HT1B receptors in regulating feeding behavior in rodents. 3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one (1) has also been shown to be biochemically discriminatory in its ability to selectively inhibit forskolin-stimulated adenylate cyclase activity only at the 5-HT1B receptor. The source of the selectivity of 1 appears to lie in the ability of a pyrrolo[3,2-b]pyrid-5-one to act as a rotationally restricted bioisosteric replacement for 5-hydroxyindole.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2374139     DOI: 10.1021/jm00170a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  26 in total

1.  Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors.

Authors:  Araceli Sánchez-Lopez; David Centurión; Erika Vázquez; Udayasankar Arulmani; Pramod R Saxena; Carlos M Villalón
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

2.  5-HT(1B) receptors inhibit glutamate release from primary afferent terminals in rat medullary dorsal horn neurons.

Authors:  I-S Choi; J-H Cho; C-H An; J-K Jung; Y-K Hur; J-K Choi; I-S Jang
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

3.  CP-93,129, a potent and selective 5-HT1B receptor agonist blocks neurogenic plasma extravasation within rat but not guinea-pig dura mater.

Authors:  T Matsubara; M A Moskowitz; B Byun
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

4.  Serotonin1B receptor stimulation enhances cocaine reinforcement.

Authors:  L H Parsons; F Weiss; G F Koob
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

5.  Tropisetron increases the inhibitory effect of mild restraint on lordosis behavior of hormonally primed, ovariectomized rats.

Authors:  Lynda Uphouse; Danyeal Heckard; Cindy Hiegel; Jutatip Guptarak; Sharmin Maswood
Journal:  Behav Brain Res       Date:  2011-01-14       Impact factor: 3.332

6.  Characterization of a 5-HT1B receptor on CHO cells: functional responses in the absence of radioligand binding.

Authors:  H Giles; S J Lansdell; M L Bolofo; H L Wilson; G R Martin
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

7.  Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain.

Authors:  A T Bruinvels; J M Palacios; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-06       Impact factor: 3.000

8.  Further characterization of the 5-HT1 receptors mediating cardiac sympatho-inhibition in pithed rats: pharmacological correlation with the 5-HT1B and 5-HT1D subtypes.

Authors:  Araceli Sánchez-López; David Centurión; Erika Vázquez; Udayasankar Arulmani; Pramod R Saxena; Carlos M Villalón
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-12-12       Impact factor: 3.000

9.  5-HT1B receptors mediate potent contractile responses to 5-HT in rat caudal artery.

Authors:  D A Craig; G R Martin
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

10.  Region-specific regulation of 5-HT1B receptors in the rat brain by chronic venlafaxine treatment.

Authors:  R Vidal; A Diaz; A Pazos; E Castro
Journal:  Psychopharmacology (Berl)       Date:  2013-04-23       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.